Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
Jenny Ouyang is an Associate Professor in the Department of Biology at the University of Nevada, Reno , where she also serves as Director of the Ecology, Evolution and Conservation Biology graduate program. She earned her B.S. and B.A. from the University of California, Irvine (2007), followed by M.A. and Ph.D. in Ecology and Evolutionary Biology from Princeton University (2009, 2012). Her research focuses on the ecology and evolution of physiological systems , particularly how hormonally regulated traits enable organismal adaptation to environmental changes like urbanization , light pollution , and endocrine stress responses . Education: Ph.D., Ecology and Evolutionary Biology, Princeton University (2012) M.A., Ecology and Evolutionary Biology, Princeton University (2009) B.S., Biology, University of California, Irvine (2007) B.A., French, University of California, Irvine (2007) Her work integrates neuroendocrine mechanisms with ecological contexts to understand phenotypic flexibility and epigenetic adaptation in birds. Recent projects examine how artificial light at night disrupts circadian rhythms, hormonal profiles, and parental behaviors across urban-rural gradients. She has secured major grants including the NSF CAREER award (2022) for studying urbanization and NIH COBRE funding (2017) as part of a neuroscience team. Key collaborations include Dr. Maria Echeverry at Universidad Pontificia Javeriana in Colombia through her 2023 Fulbright award . The Ouyang Lab combines natural and laboratory experiments to investigate stress physiology, with recent papers analyzing glucocorticoid responses to urbanization, gene expression patterns under light pollution, and epigenetic reorganization in response to environmental stressors. Her publications span top journals like Proceedings of the Royal Society B , Biology Letters , and Ecology Applications , where her 2022 paper on lead pollution and reproduction was highlighted by ESA and Swedish Radio. Scientific Awards & Recognition: US Fulbright Scholars Award (2023) NSF CAREER grant (2022) NIH COBRE grant (2017) as team member Advising students like Valentina Alaasam (NSF GRFP awardee) and Ivan Celso Carvalho Provinciato (Dean's Merit Fellowship)
Qiaowei Pan is a Researcher at the University of Lausanne , focusing on Evolution and Ecology . They have held a Guest Researcher role at the Institute of Molecular Biology gGmbH (IMB) in Mainz, Germany since 2023, and a Postdoctoral Researcher position at the University of Lausanne since 2018. Education: PhD in Molecular and Evolutionary Biology (2014-2018), INRAe, University of Rennes II, France Erasmus Mundus Master in Evolutionary Biology (MEME) (2012-2014), University of Groningen (Netherlands) & University of Montpellier II (France) BSc in Biology (2008-2012), University of North Carolina-Chapel Hill, USA Research Interests: Qiaowei Pan's work centers on the intersection of molecular genetics , evolutionary biology , and developmental biology , particularly in sex determination mechanisms across diverse animal models. Their studies span non-coding RNA regulation , sex chromosome evolution , and signal transduction pathways like TGF-β in reproductive systems. Publication Trends: Recent articles highlight expertise in sex determination systems (5/12 publications), genomic approaches (6/12), and fish developmental evolution . Collaborative work includes computational methods ( RADSex workflow ) and comparative studies across ant , goldfish , catfish , and cavefish models. Labs & Teams: Currently affiliated with the Keller-Valsecchi group at IMB and the Department of Evolution and Ecology at the University of Lausanne.
Fei-Fei Li is the Sequoia Capital Professor in Computer Science at Stanford University and Founding Co-Director of the Stanford Institute for Human-Centered AI (HAI). She holds courtesy appointments in the Graduate School of Business and is a Senior Fellow at HAI. Her work bridges AI research with interdisciplinary applications in healthcare, robotics, and policy. Dr. Li pioneered the ImageNet dataset, instrumental in the AI revolution, and co-founded World Labs to advance spatial intelligence and generative AI. Education: B.A. in Physics, Princeton University (1999) Ph.D. in Electrical Engineering, Caltech (2005) Doctorate (Honorary), Harvey Mudd College (2022) Research Interests: AI ethics, computer vision, robotic learning, healthcare applications, and human-AI collaboration. Her teams developed frameworks like MOMA for activity recognition and BEHAVIOR for embodied AI benchmarks. She advocates for diversity in tech and co-founded AI4All to mentor underrepresented students. Key Contributions: ImageNet and ImageNet Challenge Stanford Vision and Learning Lab (SVL) Policy advisory roles for U.S. Senate, UN Secretary-General, and California Governor Labs & Initiatives: Leads the People, AI & Robots Group (PAIR), Partnership in AI-Assisted Care (PAC), and the Human-Centered AI Institute. Her work emphasizes ethical AI deployment and societal impact. Awards: VinFuture Prize (2024), IEEE Fellow, National Academy memberships (Engineering, Medicine, Arts & Sciences), and recognition as one of Time’s AI100 Influencers.
Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.
California Institute of Technology (Caltech)United States
Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.
University of California, Los AngelesUnited States
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Kora DeBeck is a Distinguished Professor of Substance Use and Drug Policy in the School of Public Policy at Simon Fraser University, a CIHR Applied Public Health Chair, and Dorothy Killam Fellow. She is also a Research Scientist with the BC Centre on Substance Use and Principal Investigator of the At-Risk Youth Study (ARYS), a longitudinal cohort tracking over 1,200 street-involved youth. Her research focuses on substance use policy, health services for marginalized populations, and the structural drivers of drug-related harms. She has published over 200 peer-reviewed articles challenging ineffective drug enforcement models and advocating for policy reforms. Recent publications analyze trends in opioid use, harm reduction during the COVID-19 pandemic, drug decriminalization, and youth-focused interventions. Her work consistently addresses social inequities through data-driven approaches to the toxic drug crisis. CIHR Applied Public Health Chair Dorothy Killam Fellow Michael Smith Health Research BC Scholar Award Distinguished SFU Professorship She has secured over $50 million in research funding, including $21M as principal investigator for ARYS. Her lab collaborates with healthcare providers, community organizations, and policymakers to translate research into practice.
Dr. Jane Gair is a tenured Teaching Professor in the Division of Medical Sciences at the University of Victoria, where she teaches first and second-year medical students in the Island Medical Program (IMP). She serves as IMP Site Lead for Case-Based Learning (CBL) and Director for CBL Faculty Development, leading provincial curriculum implementation and faculty training. Her academic credentials include: BSc from McMaster University BSc from University of British Columbia (UBC) PhD from University of British Columbia (UBC) Her research centers on medical education methodologies including Problem-Based Learning (PBL) and Case-Based Learning (CBL), with emphasis on small-group pedagogy effectiveness. She maintains active scholarship in medical genetics and personalized medicine, as demonstrated through public lectures on epigenetics and genetic testing. International collaborations extend her work to the University of Newcastle (Australia), Patan Academy of Health Sciences (Nepal), and National University of Defense Technology (China). Dr. Gair directs UVic's branch of the national Let's Talk Science Outreach Program, engaging medical students in K-12 STEM education across Vancouver Island. This initiative serves as a core component of the FLEX course curriculum where she mentors students as Advisor, Assessor, and Supervisor. Her provincial faculty development work indicates ongoing grant-supported activities though specific funding sources aren't detailed. She maintains affiliations with the Centre for Biomedical Research (CBR) at UVic and the Centre for Health Education Scholarship (CHES) at UBC. Her leadership in Let's Talk Science coordinates medical student volunteers and community partners in delivering science literacy programs, with recent activities including 2023-2024 Mini Med School sessions on AI in healthcare, diabetes management, and genetic testing.
Dewey G. McCafferty is Professor of Chemistry at Duke University with appointments in Biochemistry and the Duke Cancer Institute. His research focuses on chemical biology of chromatin-modifying enzymes and ubiquitin signaling pathways relevant to neurodegeneration and infection. Notable work includes discovering the lasso peptide antibiotic Arcumycin, characterizing the Nedd4 ubiquitin ligase in Parkinson's disease models, and developing chemoproteomic approaches for target identification. Key contributions include elucidation of the futalosine pathway in Chlamydia infections, mechanisms of CPAF protease in bacterial pathogenesis, and engineering of histone demethylase enzymes. McCafferty received the Eli Lilly Award in Biological Chemistry (2005) and directs NIH-funded projects on ubiquitin ligases in neurodegeneration.